Vivek Subbiah: Health-Related Quality of Life in KRASG12C-Mutated Colorectal Cancer
Vivek Subbiah, Chief, Early-Phase Drug Development at Sarah Cannon Research Institute, shared on X about a recent paper by Dominik Paul Modest et al. published on The Lancet Oncology:
“Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial – The Lancet Oncology.”
Title: Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial
Authors: Prof Dominik Paul Modest, Prof Marwan Fakih, Lisa Salvatore, Taito Esaki, David Páez Lopez-Bravo, Julien Taieb, Michalis Karamouzis, Erika Ruiz-Garcia, Tae Won Kim, Yasutoshi Kuboki, Fausto Meriggi, David Cunningham, Kun-Huei Yeh, Chiara Cremolini, Qui Tran, Emily Chan, Joseph Chao, Istvan Matyas Majer, Filippo Pietrantonio.
More posts featuring Vivek Subbiah.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023